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Abstract 
A 70-year old male was referred to our attention for worsening dyspnea in the last three months. His past 
medical history was characterized by an acute myocardial infarction and an episode of ventricular 
tachycardia with positioning of an implantable cardioverter defibrillator. At the physical examination 
“velcro” inspiratory crackles were present, however lung volumes, diffusing capacity of the carbon 
monoxide and arterial blood gases values were within the normal limits, whereas the computed 
tomography of the chest showed a typical pattern of idiopathic pulmonary fibrosis. Long-term treatment 
with pirfenidone was started.  
Conclusions:Idiopathic pulmonary fibrosis is a rare chronic, progressive lung disease that may present 
with progressive dyspnea which may be confused with cardiogenic dyspnea.  
 
KeyWords:: Idiopathic Pulmonary Fibrosis; dyspnea; heart 
failure. 
 
 
Introducing Member: Gaetano Caramori 
Corresponding Author: Paolo Ruggeri - plruggeri @unime.it 
 
Introduction 
Idiopathic pulmonary fibrosis (IPF) is a speciﬁc form of chronic, progressive ﬁbrosing interstitial 
pneumonia of unknown cause occurring in adults (1).It is usually chronic and progressive, with 
characteristic imaging and histologic appearances, that occurs primarily in older adults and is 
often fatal. This disease is frequently misdiagnosed by internal medicine specialists and primary 
care physicians (2). Cardiac comorbidities are often associated with IPF and the differential 
diagnosis may be difficult (3). 
Case report 
The case concerns a 70-year-old, formerly employed as a bakery, who presented to our attention 
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for worsening dyspnea in the last three months. He was a former smoker (he quitted in 1998) of 
25 pack-years, with a long history of systemic arterial hypertension [treated with ramipril (10 mg 
daily)] and diabetes mellitus [treated with metformin (400 mg twice daily ) and glibenclamid (2.5 
mg twice daily)] and dyslipidemia [treated with rosuvastatin (10 mg daily)]. He had an anxiety 
depressive disorder treated with lorazepam (1 mg daily).His past medical history was 
characterized by an acute myocardial infarction (30 years before the presentation) and (2011) an 
episode ventricular tachycardia with positioning of an implantable cardioverter defibrillator.At 
the hospital admission, the systemic blood pressure was 135/75 mmHg with a pulse frequency of 
96 bpm (rhythmic) and a body axillary temperature of 36°C. His height was 163 cm with a 
weight of 84 Kg and a body mass index of 31 Kg/m2. Physical examination of the chest revealed 
the presence of bilateral “velcro” inspiratory crackles on basal lung fields at lung auscultation. No 
other physical signs outside the chest were pathological. Routine laboratory tests were normal. A 
panel of serum auto antibodies is presented in Table 1. 
 
Table 1. Panel of serum auto antibodies 
Parameters Value Normal Range 
ANA 1:160 ≤ 1:80 
ASMA 1:80 negative 
Rheumatoid factor 7 IU/ml 0-14 IU/ml 
ANA:antinuclear antibodies; ASMA:anti-smooth muscle antibodies 
Lung volumes, diffusing capacity of the carbon monoxide and arterial blood gases values were within the normal limits (Fig.1). 
 
The six-minute walk test showed a distance of 
175 meters (23% of the predicted value) 
associated with oxygen desaturation (minimum 
value of SpO2=90%) and dyspnea (score 2 of 
the visual Borg scale 1-10 where ten was the 
most intense degree).  The echocardiography 
revealed a reduced ejection fraction (50%; nv > 
55%) and normal pulmonary artery systolic 
pressure. The high resolution computed 
tomography of the chest showed a typical 
pattern of idiopathic pulmonary fibrosis 
according to the Fleischner Society criteria 
(Fig.2) (4). Further more invasive diagnostic 
tests were not performed.  
 
 
 
Fig. 2.High resolution  computed tomography of the chest showed a 
typical UIP characterized by  the presence of honeycombing (open 
arrow) and reticular pattern (closed arrow) located in the basal 
and subpleural regions of the lung. 
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Long-term treatment with pirfenidone (267 mg three times daily) and omeprazole (40 mg daily) 
was started together with long-term follow-up of the patient according to current guidelines (1).  
Discussion 
IPF is the most common type of idiopathic interstitial pneumonia (IIP), that is more common in 
male smokers ≥50 years old (5). The most favored conceptual model of the pathogenesis of IPF 
posits that recurrent, subclinical epithelial injury superimposed on accelerated epithelial aging 
leads to aberrant repair of the injured alveolus and deposition of interstitial fibrosis by 
myofibroblasts (2). Every clinician should consider this interstitial lung disease in the differential 
diagnosis of all adults presenting with unexplained exertional dyspnea typically progressing over 
a period of month to years and associated with chronic dry cough and/or velcro-like crackles on  
 
Figure 1.Lung volumes, diffusing capacity for the carbon monoxide and arterial blood gases values were within the normal limits 
 
Parameters Unit Ref Pre Pre%Ref 
FEV1 Liters 2.49 2.32 93 
FVC Liters 3.22 2.60 81 
FEV1/FVC % 75 85  
FEF25-75% L/sec 2.86 3.69 129 
PEF L/sec 7.16 5.17 72 
TLC-He Liters 5.95 4.79 80 
FRC-He Liters 3.36 2.80 83 
RV-He Liters 2.44 1.94 79 
RV/TLC-He %  42  
TLCO mmol/min/kPa 7.47 6.20 83 
KCO mmol/min/kPa/L 1.30 1.40 108 
pH  7.35-7.45 7.44  
PaO2 mmHg 80-100 85  
PaCO2 mmHg 35-45 35.8  
Serum bicarbonates mmol/L 22-26 24  
SaO2 % 94-100 96  
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examination (2). In fact, the lung auscultation of basal bilateral velcro-like crackles has an 
excellent sensitivity and good specificity for the diagnosis of IPF (6). These sounds are different 
from adventitious sounds associated with heart failure (7).A detailed medical history is of 
fundamental importance for the differential diagnosis with other chronic secondary fibrosing lung 
disease, such as chronic hypersensitivity pneumonitis and pneumoconiosis (4). When the 
computed tomography of the chest pattern is indicative of typical or probable UIP (usual 
interstitial pneumonia) the diagnosis is confident (4). Whereas in the presence of a CT pattern 
indeterminate for UIP, more invasive diagnostic tests (including lung biopsy) may be considered, 
according the general clinical conditions of the patient and his/her preferences (4). The incidence 
of exacerbations in the patients with IPF is variable with a 1 and 3-years incidence raging 
between 8.6% and 23.9% (8). Due to the current absence of effective therapies and the high 
mortality (median life expectancy of 2.2 months) a new definition of IPF exacerbation has been 
proposed including all causes of respiratory deterioration except for acute heart failure and 
volume overload (9). The majority of patients with IPF have comorbidities, particularly gastro-
oesophageal reflux (prevalence ranged from 5% to 94%), that may result in more frequent 
exacerbations, rapid decline of lung function and reduced survival (3).Currently in Italy there are 
two drugs (nintedanib and pirfenidone)  approved for the long-term treatment of IPF both have 
shown to significantly reduce the decline of  lung function (forced vital capacity) and the number 
and severity of exacerbations leading to hospitalization, but do not reduce significantly the 
mortality (2). Lung transplantation can improve survival among patients with IPF so transplant 
discussion was recommended at the time of diagnosis (10). In conclusion, idiopathic pulmonary 
fibrosis is a rare chronic, progressive lung disease that may present with progressive dyspnea 
which may be confused with cardiogenic dyspnea.  
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